Joint research team develops world's 1st oral microbiome-based nanodrug for cancer immunotherapy
Researchers at Sungkyunkwan University and the University of Michigan have developed the world’s first oral microbiome-based nanodrug for cancer immunotherapy. Sungkyunkwan University said Monday that the nanodrug significantly enhances the ability of immune cells to attack cancer cells by using natural metabolites produced by gut bacteria. The university’s research team, led by Cho Young-seok,…
Researchers at Sungkyunkwan University and the University of Michigan have developed the world's first oral microbiome-based nanodrug for cancer immunotherapy. The nanodrug, created by a team led by Professor Cho Young-seok from Sungkyunkwan University's School of Medicine, utilizes natural metabolites produced by gut bacteria to enhance the immune system's ability to target cancer cells.
This groundbreaking study, published in the prestigious journal Nature Nanotechnology, represents the first molecular-level understanding of how gut microbes influence immune function and how to translate this knowledge into an orally administered drug using nanotechnology. Professor Cho emphasized that the discovery opens new avenues for cancer treatment, as the nanodrug significantly boosts the effectiveness of immune cells in attacking cancer cells.
The research collaboration between the two universities resulted in a significant breakthrough that could potentially revolutionize cancer immunotherapy.
Written by urgent.news from The Korea Times's reporting — not their text. Machine-written — it may contain errors, so check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
